vorasidenib
servier
['vorasidenib', 'indigo']
late breaking at #asco23: mutations in idh 1 or 2 in low-grade glioma in recurrent or residual disease. the idh inhibitor vorasidenib improved pfs as compared with placebo. full results of the #indigo phase 3 trial: 
Fellowship Program Director 👨‍🏫 Hematology & Oncology at George Washington University. Thoracic and Head&Neck cancer.